ClinicalTrials.gg
CompletedNCT06196580Updated Mar 6, 2024

PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval

A Phase 1 interventional study of repaglinide; midazolam; SHR4640 and repaglinide; midazolam; SHR4640; SHR4640 placebo in Gout and Hyperuricemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Gout · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
9th of 11
24 · median 50
Started
2024
with 1 other
Phase 1
7 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd., this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 1, and was the 10th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Gout, anywhere →

Where they have run

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The purpose of this study is to evaluate the PK effects of SHR4640 tablets on repaglinide and midazolam, as well as the effects of SHR4640 tablets on the QT interval in healthy subjects.

03

Conditions studied

  • Gout and Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form before the start of the trial-related activities, and be able to understand the procedures and methods of the trial, and are willing to strictly comply with the clinical trial protocol to complete the trial;
  2. Aged 18 to 45 years old (both ends included, subject to the time of signing the informed consent form), male or female;
  3. Male weight ≥ 50 kg, female weight ≥ 45 kg, and (BMI): 19-26 kg/m2 (both ends included);
  4. No fertility plan and agree to take non-drug high-efficiency measures (see appendix 1 for details) within 28 days from signing the informed consent form to the last administration of the trial drug, and no plans for sperm donation or egg donation.

Exclusion criteria

Exclusion Criteria:

  1. Individuals who have a history of smoking within the 3 months before signing the form (average daily smoking>5 cigarettes) or who cannot stop using any tobacco products during the study period;
  2. The average daily intake of alcohol in the three months before signing the informed consent is more than 7 g for women (about 200 ml beer, 70 ml wine or 22 ml low-alcohol liquor) and 14 g for men (about 400 ml beer, 140 ml wine or 45 ml low-alcohol liquor); Those who cannot abstain from alcohol during the trial;
  3. Within the first 7 days of randomization, consumed any beverage or food containing grapefruit; Or have eaten any beverages or foods containing methylxanthines, such as coffee, tea, cola, chocolate, etc., within the previous 2 days at random;
  4. Allergic constitution, or allergic or suspected allergic to SHR4640 tablets, repaglinide or midazolam;
  5. Drug abusers, or those who have positive urinary abuse during screening;
  6. any history of severe clinical disease or conditions that the researcher believes may affect the results of the trial, including but not limited to the history of circulatory, endocrine, nervous, digestive, urinary, or blood, immune, psychiatric, and metabolic diseases;
  7. Patients with of repaglinide (type 1 diabetes, C-peptide negative diabetes patients, diabetes ketoacidosis patients with or without coma);
  8. Patients with contraindications to midazolam (acute angle closure glaucoma, severe respiratory insufficiency, sleep apnea syndrome, myasthenia gravis, schizophrenia, and severe depressive state);
  9. During screening, vital signs, physical examinations, laboratory tests, cardiac ultrasound, abdominal ultrasound, or chest imaging examinations indicate the presence of abnormalities that are according to the judgment of the investigator;
  10. When screening, ultrasound examination of the urinary system indicates the presence of stones or crystals in the urinary system;
  11. Individuals with acute kidney injury before screening or random ;
  12. Individuals with serum uric acid higher than 420 μmol/L at screening, , or a history of hyperuricemia and/or gout disease;
  13. Individuals with >450 ms, PR interval>200 ms, QRS complex time limit>120 ms, or HR>100 bpm, or other abnormalities that were clinically significant as determined by the researcher;
  14. Individuals with risk factors for torsade de pointe ventricular tachycardia, such as heart failure, hypokalemia, short QT syndrome, long QT syndrome, or a first-degree relatives family history of unexplained sudden death, drowning, or sudden infant death syndrome in young adulthood (≤ 40 years old);
  15. Individuals with positive surface antigen (HBsAg), or anti- virus (HCV) antibodies, or (HIV) antibodies, or syphilis antibodies during screening;
  16. Individuals who have used any prescription drugs, over-the-counter drugs, herbal medicines, or dietary supplements within two weeks before randomization;
  17. Systemic treatment with cytochrome P450 3A4 enzyme (), CYP2C8 inhibitor or inducer drugs used within the first 4 weeks of randomization ;
  18. Individuals (excluding screening failures) who have participated in any other drug or medical device clinical trials within 3 months before randomization or within 5 half-lives of the trial drug (whichever is longer);
  19. Individuals who have undergone any surgery within three months before randomization, or have not recovered after surgery, or plan to undergo surgery during the trial;
  20. Individuals who have donated (or lost) blood within three months before randomization and the amount of blood donated (or lost) is ≥400 mL, or received blood transfusion;
  21. According to the judgment of the researchers, subjects with conditions that affect drug absorption, distribution, metabolism, and excretion, or other factors that are not suitable for participation in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    SHR4640 group A

    Drug: repaglinide; midazolam; SHR4640

  • Experimental
    SHR4640 group B

    Drug: repaglinide; midazolam; SHR4640; SHR4640 placebo

  • Placebo comparator
    SHR4640 Placebo

    Drug: repaglinide; midazolam; SHR4640 placebo

Interventions

  • Drugrepaglinide; midazolam; SHR4640

    Drug pages: Repaglinide · Midazolam · Ruzinurad

    repaglinide; midazolam; SHR4640

  • Drugrepaglinide; midazolam; SHR4640; SHR4640 placebo

    repaglinide; midazolam; SHR4640; SHR4640 placebo

  • Drugrepaglinide; midazolam; SHR4640 placebo

    repaglinide; midazolam; SHR4640 placebo

06

What researchers measure

Primary outcomes

  1. The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: Cmax

    Time frame: Day 1 to Day 24

  2. The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: AUC0-t

    Time frame: Day 1 to Day 24

  3. The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: AUC0-inf

    Time frame: Day 1 to Day 24

  4. QTcF corrected for baseline and placebo after oral administration of SHR4640 tablets( ΔΔ QTcF)

    Time frame: Day 1 to Day 24

Secondary outcomes

  1. The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: Tmax

    Time frame: Day 1 to Day 24

  2. The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: t1/2

    Time frame: Day 1 to Day 24

  3. The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: CL/F

    Time frame: Day 1 to Day 24

  4. The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: Vz/F

    Time frame: Day 1 to Day 24

  5. PK parameters for oral SHR4640 tablets: Cmax

    Time frame: Day 1 to Day 24

  6. PK parameters for oral SHR4640 tablets: AUC0-t

    Time frame: Day 1 to Day 24

  7. PK parameters for oral SHR4640 tablets: Tmax

    Time frame: Day 1 to Day 24

  8. Safety indicators: adverse events

    Time frame: Screening period up to Day 28

07

Study locations

1 site
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 300041, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Feb 2024, 1 month.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 1 month is below that.

Counting every sponsor, half of 41 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2023
First posted
Jan 9, 2024
StartActual
Jan 4, 2024
Primary completionActual
Feb 16, 2024
CompletionActual
Feb 16, 2024
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06196580
Responsible party
Sponsor
First posted
Jan 9, 2024
Start date
Jan 4, 2024
Primary completion
Feb 16, 2024
Completion
Feb 16, 2024
Last update
Mar 6, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Repaglinide · Midazolam · Ruzinurad

Start the discussion